Medpace (NASDAQ:MEDP) is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting. Medpace also provides laboratory, imaging and other specialized services designed to support the collection, analysis and submission of clinical research data.
Founded in 1992, Medpace is headquartered in Cincinnati, Ohio, and serves clients through operations in North America, Europe, Asia and Latin America. The company focuses on a range of therapeutic areas, including oncology, cardiovascular and metabolic diseases, central nervous system disorders, and medical devices.
Medpace is led by founder August J. Troendle, who serves as chairman and chief executive officer. Its shares trade on the Nasdaq Stock Market under the symbol MEDP.
